Regeneron: The Turnaround Is Gaining Steam [Seeking Alpha]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Seeking Alpha
Dupixent and Libtayo are expected to drive robust revenue and margin expansion, with Dupixent collaboration revenues set to increase as the accounting development balance is paid off by Q3 2026. Multiple pipeline catalysts are upcoming in 2026—including Fianlimab, Lynozyfic, and Trevogrumab + Semaglutide—that could accelerate growth and re-rate REGN's valuation. I reiterate my strong buy rating, targeting $1200/share or 20x potential $60/share 2026 earnings as REGN transitions to renewed growth and higher multiples. gpointstudio/iStock via Getty Images Earlier this year, I became bullish on shares of Regeneron Pharmaceuticals REGN following FDA approval of Libtayo for adjuvant treatment of cutaneous squamous cell carcinoma [CSCC]. Libtayo's commercialization began to positively impact earnings by This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of REGN either through stock ownership, options, or other derivatives. I wrot
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Drug Sector on a High as 9 Drugmakers Strike Drug Pricing Deals [Yahoo! Finance]Yahoo! Finance
- Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation [Yahoo! Finance]Yahoo! Finance
- Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovationGlobeNewswire
- Weekly Recap: 13 Health Press Releases You Need to See [Yahoo! Finance]Yahoo! Finance
- Global Pulmonary Embolism Market Set for Growth with Increasing DVT and PE Cases [Yahoo! Finance]Yahoo! Finance
SNY
Sec Filings
- 12/15/25 - Form 6-K
- 12/12/25 - Form 6-K
- 12/3/25 - Form 6-K
- SNY's page on the SEC website